Currus Biologics Pty

Company snapshot

Currus Biologics is developing its proprietary BEAT (Bispecific Engagers of Antigen Presenting Cells and T cells) platform to unlock CAR T-cell therapy for solid tumours. The BEAT (Bispecific Engagers of Antigen presenting cells and T cells) is a universal solution compatible with any CAR T-cell format or tumour target, able to rewire immune activation by simultaneously engaging antigen-presenting

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Currus Biologics Pty. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Currus Biologics Pty.

1. Jun 8, 2026 Clinical update

   HS-19-647 — Phase 3

2. Jun 8, 2026 Clinical update

   HS-24-787 — Phase 1

3. Jun 8, 2026 Clinical update

   HS-19-657 — Phase 3

View all clinical trial activity →

• What is Currus Biologics Pty?

  Camurus Pty is a pharma organization headquartered in AU. Primary therapeutic focus areas include Body weight management, Acromegaly, gastroenteropancreatic neuroendocrine tumors. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity

• Is Currus Biologics Pty publicly traded?

  Currus Biologics Pty appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Currus Biologics Pty develop or market?

  We link 14 drug profile(s) where Currus Biologics Pty is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/camurus-ab#company-drugs.

• What are the latest developments for Currus Biologics Pty?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Currus Biologics Pty focus on?

  Currus Biologics Pty focuses on Body weight management, Acromegaly, gastroenteropancreatic neuroendocrine tumors based on our analysis of their pipeline programs and drug development activities.